Article Text

PDF

Amoxicillin resolved otitis media symptoms in young children better than did placebo at day 4 but not at day 11
  1. Christopher B Del Mar, MD, BChir, MA
  1. University of Queensland Herston, Queensland, Australia

    Statistics from Altmetric.com

    
 
 QUESTION: In children with acute otitis media (AOM) who are 6–24 months of age, how effective is amoxicillin in improving signs and symptoms?

    Design

    Randomised (allocation concealed*), blinded (clinicians and parents),* placebo controlled trial with 6 week follow up.

    Setting

    53 general practices in the Netherlands.

    Patients

    240 children who were between 6 and 24 months of age (mean age 13 mo, 54% boys) and had AOM and ≥1 symptom of acute infection (fever, recent earache, general malaise, or recent irritability). Exclusion criteria were antibiotic therapy in the past 4 weeks, allergy to amoxicillin, compromised immunity, craniofacial abnormalities, or Down's syndrome. Follow up was 91% at 11 days and 88% at 6 weeks.

    Intervention

    Patients were allocated to amoxicillin suspension, 40 mg/kg of body weight per day (n=117), or placebo (n=123) for 10 days.

    Main outcome measures

    Persistent symptoms at day 4 (earache, fever ≥38°C, crying, irritability, or prescription of another antibiotic). Secondary outcomes were clinical treatment failure at day 11 (persistent fever, earache, crying, irritability, or no improvement in appearance of the tympanic membrane); middle ear effusion at 6 weeks (assessed by otoscopy and tympanometry); and adverse effects.

    Main results

    At day 4, fewer patients who received amoxicillin had persistent symptoms than those who received placebo (p=0.03) (table). The difference was sustained after adjustment for unequal baseline characteristics between the groups (table). At day 11, the groups did not differ for clinical treatment failure (p=0.35) (table). Amoxicillin group patients had less time to cessation of fever (median time to cessation 2 v 3 d, p=0.004) but did not differ from placebo group patients for pain or crying (time to cessation 8 v 9 d, p=0.43). Amoxicillin group patients took fewer analgesics (mean over 10 d, 2.3 v 4.1 doses; p=0.004). The groups did not differ for middle ear effusion at 6 weeks {p=0.74} or for adverse effects (diarrhoea at d 4, {p=0.32}).

    Amoxicillin v placebo for children ≤2 years of age with acute otitis media‡

    Conclusions

    In children ≤2 years of age with acute otitis media, amoxicillin leads to resolution of more symptoms after 4 days of treatment. After 11 days, amoxicillin did not differ from placebo.

    Commentary

    Systematic reviews of the literature have reached the conclusion, surprising to many clinicians, that antibiotics play only a small part in resolving symptoms of AOM. Children recover without antibiotics, a finding that may influence us to use the medications less frequently.

    One problem we have, however, is the occurrence of AOM in very young children (≤2 y of age). Are they more vulnerable to AOM, and would they thus respond better to antibiotics? The 2 meta-analyses on the subject do not address this issue because none of the included trials enrolled very young children and infants.1, 2 Fortunately, we now have this well done trial by Damoiseaux et al that includes children 6–24 months of age.

    The results are similar to those for older children. Children receiving antibiotics had a statistically significant benefit, but the size of the benefit was only modest. 7 to 8 children must be treated to reduce the chance of 1 still having symptoms at day 4. By day 11, the treatment groups did not differ. This NNT is slightly better than (but in the same order as) the NNT of about 17 for older children.1

    Physicians still concerned about serious complications from AOM may take heart from an open, uncontrolled trial done in the Netherlands.3 A policy of using only nose drops and analgesics for AOM by 60 general practitioners resulted in 126 of 4860 children having an unsatisfactory course (and hence requiring antibiotics) and then only to the extent of the illness continuing beyond 3–4 days or having ear discharge 2 weeks later.

    References

    View Abstract

    Footnotes

    • Sources of funding: Netherlands Organisation for Scientific Research. Nasivin nose drops supplied by E Merck Nederland BV.

    • For correspondence: Dr R A Damoiseaux, Department of General Practice, University Medical Centre, Universiteitsweg 100, 3584 CG Utrecht, the Netherlands. Fax +31 30 2539028.

    • * See glossary.

    • p Values calculated from data in article.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.